292 related articles for article (PubMed ID: 33969517)
1. Clinical characteristics and disease burden in prurigo nodularis.
Aggarwal P; Choi J; Sutaria N; Roh YS; Wongvibulsin S; Williams KA; Huang AH; Boozalis E; Le T; Chavda R; Gabriel S; Kwatra SG
Clin Exp Dermatol; 2021 Oct; 46(7):1277-1284. PubMed ID: 33969517
[TBL] [Abstract][Full Text] [Related]
2. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.
Janmohamed SR; Gwillim EC; Yousaf M; Patel KR; Silverberg JI
Arch Dermatol Res; 2021 Oct; 313(8):669-677. PubMed ID: 33108524
[TBL] [Abstract][Full Text] [Related]
3. INDIVIDUAL ARTICLE: Prurigo Nodularis: Current Clinicopathologic Overview and Psychodermatological Perspectives.
Issa NT; Riva H; Jafferany M
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s6-SF365502s11. PubMed ID: 38051853
[TBL] [Abstract][Full Text] [Related]
4. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
5. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.
Pereira MP; Basta S; Moore J; Ständer S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2224-2229. PubMed ID: 29869425
[TBL] [Abstract][Full Text] [Related]
6. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.
Murota H; Arima K; Yoshida T; Fujita H
J Dermatol; 2024 Feb; 51(2):223-233. PubMed ID: 38066728
[TBL] [Abstract][Full Text] [Related]
7. A review of the current management and burden of prurigo nodularis in the United States.
Chisolm SS
Am J Manag Care; 2023 May; 29(5 Suppl):S63-S72. PubMed ID: 37146288
[TBL] [Abstract][Full Text] [Related]
8. Patient Perspectives on Living With Severe Prurigo Nodularis.
Rodriguez D; Kwatra SG; Dias-Barbosa C; Zeng F; Jabbar Lopez ZK; Piketty C; Puelles J
JAMA Dermatol; 2023 Nov; 159(11):1205-1212. PubMed ID: 37728897
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
10. Prurigo nodularis: Epidemiology and clinical features.
Huang AH; Williams KA; Kwatra SG
J Am Acad Dermatol; 2020 Dec; 83(6):1559-1565. PubMed ID: 32454098
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and economic burden of prurigo nodularis.
Whang KA; Le TK; Khanna R; Williams KA; Roh YS; Sutaria N; Choi J; Gabriel S; Chavda R; Semenov Y; Kwatra SG
J Am Acad Dermatol; 2022 Mar; 86(3):573-580. PubMed ID: 34058278
[TBL] [Abstract][Full Text] [Related]
12. Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden.
Pereira MP; Farcas A; Zeidler C; Ständer S
Acta Derm Venereol; 2021 Sep; 101(9):adv00550. PubMed ID: 34405244
[TBL] [Abstract][Full Text] [Related]
13. [Psychosomatic aspects of prurigo nodularis].
Schneider G; Hockmann J; Stumpf A
Hautarzt; 2014 Aug; 65(8):704-8. PubMed ID: 25113329
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
[No Abstract] [Full Text] [Related]
15. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
16. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
17. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
18. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.
Taghaddos D; Savinova I; Abu-Hilal M
J Cutan Med Surg; 2024; 28(2):141-145. PubMed ID: 38281092
[TBL] [Abstract][Full Text] [Related]
20. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
